Get the Stockscreener App
21.45
1.51%
0.21
Palvella Therapeutics Inc stock is traded at $21.45, with a volume of 7,488.
It is up +1.51% in the last 24 hours and down -2.22% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$21.24
Open:
$21.29
24h Volume:
7,488
Relative Volume:
0.09
Market Cap:
$289.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-14.85%
1M Performance:
-2.22%
6M Performance:
+82.87%
1Y Performance:
+0.00%
1-Day Range:
$20.78
$22.03
1-Week Range:
$20.78
$26.65
52-Week Range:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
21.75 | 289.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.82 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.17 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.10 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.14 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - marketscreener.com
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World
Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa
Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com
Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com
Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune
Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan
Brokers Set Expectations for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MyChesCo
Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria
Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palvella Therapeutics Reports Strong Q1 Financial Results - TipRanks
PALVELLA THERAPEUTICS Earnings Results: $PVLA Reports Quarterly Earnings - Nasdaq
PALVELLA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella's Breakthrough Skin Disease Treatment Hits Major Milestone as Phase 3 Trial Surpasses Target - Stock Titan
Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday - Defense World
Palvella Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Palvella Therapeutics Rings the Opening Bell - Nasdaq
Palvella Therapeutics to Ring Nasdaq Opening Bell - MyChesCo
Palvella Therapeutics to Host First Quarter 2025 Financial - GlobeNewswire
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):